In Its Latest Gene Therapy Gambit, Novartis Is Paying $800 Million Upfront To Acquire The Syncona-Backed Biotech, With Another $700 Million Reserved For Milestones.Novartis Has Been Diving Deep Into Retinal Disorders, And Gyroscope
Found this useful? Share it with your team.
